搜索结果


   DIO1

靶点ID:TCMBANKGE012380


靶点别名:5DI; TXDI1


靶点描述:iodothyronine deiodinase 1


染色体:1


染色体位置:1p32.3


靶点类型:protein-coding


HERB_ID:HBTAR001051


HGNC_Link:2883


OMIM_Link:147892


Ensembl_Link:ENSG00000211452


   靶点对应的植物
ID 拉丁名 药名 药用植物名 功能与主治 来源 药用部位 使用民族

   靶点对应的化合物
化合物ID 化合物名 别名 分子式 分子质量 Smiles
TCMBANKIN002083 3,3',5'-triiodothyronine C15H12I3NO4 650.97 g/mol C1=CC(=C(C=C1CC(C(=O)O)N)I)OC2=CC(=C(C(=C2)I)O)I
TCMBANKIN010852 Tuberosine B tuberosine b 193.22 C1CNC2=CC=CC=C2C1(C(=O)O)O
TCMBANKIN020961 morin SMR000058259; C.I. Natural Yellow 8; NCGC00015672-12; KBioGR_002268; 480-16-0; SPBio_000929; 8NFQ3F76WR; 5-18-05-00492 (Beilstein Handbook Reference); NCGC00022214-05; ZINC03881558; BDBM26658; DivK1c_000958; Zlut prirodni 11; NCGC00178000-02; morin ; NCGC00022214-03; 2-(2,4-Dihydroxyphenyl)-3,5,7-trihydroxy-4H-chromen-4-one #; NCI60_001647; NCGC00015672-04; ST50308676; Morin; X1189; MCULE-2387347344; 3,7,2',4'-Pentahydroxyflavone; Zlut prirodni 11 [Czech]; NCGC00015672-09; 2',3,4',5,7-Pentahydroxy-Flavone; AX8140380; C10105; HMS3262K14; NCGC00015672-02; Bio-0589; CTK5B4214; ZX-AT022489; Bois d'arc; NCGC00015672-05; 2',4',5,7-Tetrahydroxyflavonol; 4CH-024478; BRD-K11590034-001-01-0; LMPK12112517; Tox21_500776; NCGC00015672-10; SC-44859; Lopac-M-4008; 2',4',5, 7-Tetrahydroxyflavan-3-ol; A-9317; BC684344; KBio2_004282; BG01594705; Al-Morin; regid855692; C.I. 75660; KBio2_006850; Spectrum_001234; D0NJ4H; C.I. Natural Yellow 11 (VAN); HMS502P20; 3,5 7 2 4-Pentahydroxyflavone; LS-69029; C.I. Natural Yellow 11; Aurantica; EINECS 207-542-9; ZINC3881558; C.I.Natural Yellow 8; 2-(2,4-Dihydroxyphenyl)-3,5,7-trihydroxy-4H-1-benzopyran-4-one, 9CI; KBio1_000958; Bois d,Arc; C15H10O7; 2-(2,4-dihydroxyphenyl)-3,5,7-trihydroxy-4H-chromen-4-one; CHEMBL28626; FT-0628989; Morin hydrate; 2',3,4',5,7-pentahydroxy flavone; NSC19801; Aluminum Ionophore I; Spectrum5_000737; DTXSID1022398; 2',4',5,7-Pentahydroxyflavone; UNII-8NFQ3F76WR; 69870_FLUKA; MLS006012034; AC1NQYUY; 3,5,7,2',4'-Pentahydroxyflavone; LP00776; 4H-1-Benzopyran-4-one, 2-2-(2,4-dihydroxyphenyl)-3,5,7-trihydroxy-; Spectrum4_001924; Toxylon Pomiferum; NCGC00015672-13; Osage Orange; Bois d'arc [French]; AI3-38057; BSPBio_003541; NCGC00015672-08; NCGC00022214-07; ST24039108; BRN 0327474; SR-01000000157-7; Osage Orange Crystals; MLS000069618; GTPL411; KB-220543; 2-(2,4-dihydroxyphenyl)-3,5,7-trihydroxychromen-4-one; SBB008853; IDI1_000958; CHEBI:75092; KBio2_001714; KBio3_002824; 2',3,5,7-Pentahydroxyflavone; I14-19447; Osage Orange Extract; 3,5,7,2',4'-Pentahydroxyflavonol; 2',4',3,5,7-Pentahydroxyflavone; MolPort-001-742-584; 2'-Hydroxypelargidenolon 1522; SPECTRUM1502259; AN-23488; NSC-19801; Lopac0_000776; SR-01000000157-2; M-8200; AK111274; Spectrum3_001941; NCGC00178000-01; Aluminum Ionophore I, Selectophore(TM), function tested; AIDS001407; 2-(2,4-dihydroxyphenyl)-3,5,7-trihydroxy-4H-1-benzopyran-4-one; KBioSS_001714; 2-(2,4-dihydroxyphenyl)-3,5,7-trihydroxy-chromen-4-one; cid_5281670; SMP1_000199; M 4008; NCGC00015672-06; Spectrum2_000715; SR-01000000157-6; MFCD00006826; AJ-46640; NCGC00022214-06; NSC 19801; I14-114104; SCHEMBL19984; 2',3,4',5,7-Pentahydroxyflavone; CCRIS 8680; ACon1_000260; 4H-1-Benzopyran-4-one, 2-(2,4-dihydroxyphenyl)-3,5,7-trihydroxy-; NCGC00015672-07; 2-(2,4-dihydroxyphenyl)-3,5,7-trihydroxy-1-benzopyran-4-one; MEGxp0_001864; 2-(2,4-dihydroxyphenyl)-3,5,7-trihydroxy-4-chromenone; 4H-1-Benzopyran-4-one, 2-(2,4-dihydroxyphenyl)-3,5,7-trihydroxy-,monohydrate; NCGC00022214-04; EU-0100776; NCGC00261461-01; P0041; Flavone,3,4',5,7-pentahydroxy-; 91A9D69E-FAB0-45CD-90E5-DEEFBADE86C1; HMS1921P12; AIDS-001407; NCGC00015672-11; BIDD:ER0115; 2',4',5,7-Tetrahydroxyflavan-3-ol; Bois d'Arc; 11128-85-1; AKOS001582671; NINDS_000958; NCGC00015672-03; Flavone, 2',3,4',5,7-pentahydroxy-; Calico Yellow; 2',5,7-Tetrahydroxyflavan-3-ol; 2-(2,4-Dihydroxyphenyl)-3,5,7-trihydroxy-4H-chromen-4-one; SDCCGMLS-0003296.P003; CCG-39036; NCGC00015672-14; NCGC00015672-01; SR-01000000157; Morin, p.a., 97.0%; 2-(2,4-dihydroxyphenyl)-3,5,7-trihydroxy-chromone; MORIN, REAG; YXOLAZRVSSWPPT-UHFFFAOYSA-N C15H10O7 302.24 C1=CC(=C(C=C1O)O)C2=C(C(=O)C3=C(C=C(C=C3O2)O)O)O
TCMBANKIN058213 kaemferol;kampferol;kaempferol;campherol TNP00039; nchembio.2007.28-comp30; Kaempherol; 5-18-05-00251 (Beilstein Handbook Reference); Prestwick2_001098; CHEBI:28499; Prestwick1_001098; CAS-520-18-3; BRN 0304401; Flavone, 3,4',5,7-tetrahydroxy-; ST030560; MEGxp0_001283; 4H-1-Benzopyran-4-one, 3,5,7-trihydroxy-2-(4-hydroxyphenyl)-5,7,4'-Trihydroxyflavonol; C.I. 75640; Swartziol; K0133_SIGMA; kaempferol oxoanion; NCGC00016480-01; 60010_FLUKA; EINECS 208-287-6; Pelargidenon; Nimbecetin; 3,5,7-trihydroxy-2-(4-hydroxyphenyl)-4-chromenone; NSC 407289; 3,4',5,7-Tetrahydroxyflavone; HSCI1_000027; Pelargidenolon 1497; NSC407289; Robigenin; C05903; CPD1F-90; Kampferol; NSC 656277; Prestwick0_001098; 3,5,7-trihydroxy-2-(4-hydroxyphenyl)chromen-4-one; Populnetin; Kampcetin; Prestwick3_001098; AIDS-001404; ZINC00137345; kaempferol ; 5,7-dihydroxy-2-(4-hydroxyphenyl)-4-oxo-4H-chromen-3-olate; 3,4′,5,7-Tetrahydroxyflavone; Rhamnolutein; NCGC00016480-02; ACon1_001867; NSC656277; 3,4′,5,7-Tetrahydroxyflavone; BSPBio_001176; SPBio_003058; Oprea1_650954; 5,7,4'-Trihydroxyflavonol; 4H-1-Benzopyran-4-one,3,5,7-trihydroxy-2-(4-hydroxyphenyl)-5,7,4'-Trihydroxyflavonol; 4H-1-Benzopyran-4-one, 3,5,7-trihydroxy-2-(4-hydroxyphenyl)- (9CI); Campherol; 520-18-3; 3,5,7-TRIHYDROXY-2-(4-HYDROXYPHENYL)-4H-CHROMEN-4-ONE; S00111; Trifolitin; Kampherol; AI3-36096; 3,5,7-trihydroxy-2-(4-hydroxyphenyl)chromone; Indigo yellow; Pelargidenolon; AIDS001404; nchembio718-comp14; NCGC00091036-01; Flavone, 3,4',5,7-tetrahydroxy- (7CI,8CI); CHEBI:58573; Kaemferol; Kempferol; BPBio1_001294; 3,5,7-Trihydroxy-2-(4-hydroxyphenyl)-4H-1-benzopyran-4-one; Rhamnolutin; 3,5,7-triOH-Flavone; KMP; CCRIS 41; 4H-1-Benzopyran-4-one, 3,5,7-trihydroxy-2-(4-hydroxyphenyl)- C15H10O6 286.24 g/mol C1=CC(=CC=C1C2=C(C(=O)C3=C(C=C(C=C3O2)O)O)O)O

   靶点对应的疾病
疾病ID 疾病名 MeSH名 HPO名 UMLS名 疾病类型
TCMBANKDI000054 Nervous System Diseases; Mental Disorders Abnormality of the nervous system Disease or Syndrome disease
TCMBANKDI002974 Neoplasms - Neoplastic Process disease
TCMBANKDI003353 Pathological Conditions, Signs and Symptoms; Neoplasms - Neoplastic Process phenotype
TCMBANKDI006055 Pathological Conditions, Signs and Symptoms; Neoplasms - Neoplastic Process disease
TCMBANKDI009231 Pathological Conditions, Signs and Symptoms; Infections Abnormality of the immune system Disease or Syndrome disease
TCMBANKDI011743 Neoplasms; Skin and Connective Tissue Diseases Neoplasm; Abnormality of the breast Neoplastic Process group
TCMBANKDI018680 Eye Diseases; Immune System Diseases; Endocrine System Diseases Abnormality of the endocrine system Disease or Syndrome disease
TCMBANKDI022233 Endocrine System Diseases - Disease or Syndrome disease